Both EMO monotherapy and its combination with RSG significantly ameliorated liver steatosis and renal dysfunction compared with RSG-treated groups, as shown by reduced serum markers of liver damage (ALT, AST) and renal impairment (CREA, UN), decreased hepatic lipid content, and improved liver weight parameters (Figure S1). Here, GPT is linked to fatty liver disease.